1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: During the three months ended June 30, 2024, no director or officer of the Company adopted , modified, or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
−Removed: Michael Monahan - Cash-Based Performance Bonus Opportunity
−Removed: The information included in this portion of Part II, Item 5 of this Quarterly Report on Form 10-Q is provided in lieu of filing such information on a Current Report on Form 8-K under Item 5.02.
−Removed: Departure of Directors or Certain Officers;
−Removed: Election of Directors;
−Removed: Appointment of Certain Officers;
−Removed: Compensatory Arrangements of Certain Officers.
−Removed: On August 6, 2024, the Company, following consultation with and under the recommendation of the Company’s Compensation Committee, issued a letter (the “Bonus Opportunity Letter”) that approved the grant of a cash-based performance bonus in the amount of $300,000 to Michael Monahan , the Company’s Chief Financial Officer (the “Cash Performance Bonus”).
−Removed: The Cash Performance Bonus will be paid in one lump sum payment on or before April 15, 2025 (the “Target Date”), provided that Mr.
−Removed: Monahan achieves the following performance goals, the satisfaction of which will be determined by the Company:
−Removed: Monahan must ensure (i) that a written remediation plan to address the Company’s Inventory Material Weakness as further described in Part I, Item 4 of this Quarterly Report on Form 10-Q is implemented by the Target Date, whereby the remediation plan must establish a process for ongoing monitoring and oversight, appropriate training, and appropriate system enhancements to address (a) physical existence of inventory, (b) excess and obsolete inventory, and (c) inventory pricing and purchase agreements, including non-trade vendor receivables and potential disputes with vendors, and (ii) that systems and processes are in place to align the Company’s sales and operational planning process with the Company’s demand planning and inventory management process.
−Removed: The foregoing description of the Bonus Opportunity Letter is qualified in its entirety by reference to the text of the Bonus Opportunity Letter, which is filed as Exhibit 10.5 to this Quarterly Report on Form 10-Q and incorporated herein by reference.
−Removed: Termination of Credit Agreement
−Removed: The information included in this portion of Part II, Item 5 of this Quarterly Report on Form 10-Q is provided in lieu of filing such information on a Current Report on Form 8-K under Item 1.02 Termination of a Material Definitive Agreement.
−Removed: On August 6, 2024, the Company prepaid all obligations and terminated all commitments, liabilities, and other obligations under the Credit Agreement.
−Removed: There were no material early termination penalties incurred in connection therewith, all outstanding obligations and commitments under the Credit Agreement were satisfied and terminated, and all related security interests and liens securing such obligations and commitments were released.
+Added: During the three months ended September 30, 2024, no director or officer of the Company adopted , modified, or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
22 unchanged sentences
4.4 March 1, 2022
−Removed: Employment Agreement, dated April 8, 2024, by and among The Beauty Health Company, HydraFacial LLC, and Marla Beck
−Removed: 001-39565 10.1 April 8, 2024
−Removed: The Beauty Health Company Amended and Restated Executive Severance Plan
−Removed: 001-39565 10.2 April 8, 2024
−Removed: Purchase Agreement, dated April 1, 2024, by and between The Beauty Health Company and Goldman Sachs & Co.
−Removed: 10-Q 001-39565 10.4 May 9, 2024
−Removed: Separation, Transition and General Release Agreement, dated April 29, 2024, by and between Hydrafacial LLC and Brad Hauser
−Removed: 10.1 May 2, 2024
Bonus Opportunity Letter, dated August 6, 2024, for Michael Monahan
−Removed: EXHIBIT INDEX
−Removed: Description of Exhibit Form
−Removed: Filed Herewith
+Added: 10-Q 001-39565 10.5 August 8, 2024
+Added: Separation and Transition Agreement, dated November 11, 2024, by and between Hydrafacial LLC and Daniel Watson
+Added: 8-K/A 001-39565 10.1 November 12, 2024
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
4 unchanged sentences
Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
+Added: EXHIBIT INDEX
+Added: Description of Exhibit Form
+Added: Filed Herewith
Inline XBRL Instance Document
13 unchanged sentences
THE BEAUTY HEALTH COMPANY
−Removed: August 8, 2024
+Added: November 12, 2024
/s/ Marla Beck
1 unchanged sentence
(Principal Executive Officer)
−Removed: August 8, 2024
+Added: November 12, 2024
/s/ Michael Monahan
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.